185750.KO Chong Kun Dang Pharmaceutical
- Market cap
- KRW 839B
- P/E
- 10.1x
- P/B
- 0.79x
- ROE
- 6.5%
- Dividend yield
- 1.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 185750.KO undervalued?
Graham number185750.KO trades 40.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chong Kun Dang Pharmaceutical fundamental analysis
No fundamental analysis for Chong Kun Dang Pharmaceutical yet.
Chong Kun Dang Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Full company profileChong Kun Dang Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chong Kun Dang Pharmaceutical annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 832B | 884B | 956B | 1.08T | 1.30T | 1.34T | 1.49T | 1.67T | 1.59T | 1.69T | 1.85T |
| Gross Profit | 335B | 360B | 380B | 404B | 489B | 496B | 543B | 662B | 533B | 526B | 529B |
| Operating Income | 61.2B | 77.8B | 75.7B | 74.6B | 124B | 94.8B | 110B | 247B | 99.5B | 80.6B | 65.4B |
| EBITDA | - | 100B | 92.3B | 98.0B | 149B | 112B | 138B | 288B | 150B | 133B | 119B |
| Net Income | 40.9B | 53.8B | 42.4B | 53.9B | 91.6B | 42.7B | 81.0B | 213B | 109B | 77.5B | 65.6B |
| EPS | - | 4,707 | 3,916 | 4,978 | 8,478 | 3,617 | 6,642 | 16,701 | 8,679 | 5,883 | 4,981 |
| Balance Sheet | |||||||||||
| Total Assets | 642B | 677B | 711B | 801B | 946B | 1.05T | 1.12T | 1.40T | 1.46T | 1.80T | 1.87T |
| Total Liabilities | 287B | 274B | 281B | 326B | 395B | 481B | 504B | 587B | 562B | 794B | 848B |
| Shareholders' Equity | 354B | 402B | 429B | 474B | 551B | 566B | 622B | 816B | 894B | 1.00T | 1.02T |
| Cash & Short-term Investments | 21.7B | 45.5B | 45.9B | 76.9B | 124B | 132B | 117B | 220B | 228B | 216B | 192B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 57.8B | 81.7B | 42.6B | 77.3B | 104B | 12.9B | 67.7B | 318B | 64.3B | 67.4B | 51.3B |
| Capital Expenditure | 39.4B | 19.8B | 21.9B | 21.8B | 32.6B | 48.2B | 44.9B | 68.8B | 66.1B | 179B | 211B |
| Free Cash Flow | - | 60.4B | 18.0B | 52.4B | 67.5B | -38.9B | 14.7B | 249B | -1.81B | -112B | -160B |
| Ratios | |||||||||||
| ROE | 11.6% | 13.4% | 9.9% | 11.4% | 16.6% | 7.5% | 13.0% | 26.1% | 12.2% | 7.7% | 6.5% |
| ROA | 6.4% | 7.9% | 6.0% | 6.7% | 9.7% | 4.1% | 7.2% | 15.2% | 7.5% | 4.3% | 3.5% |
| Net Profit Margin | 4.9% | 6.1% | 4.4% | 5.0% | 7.0% | 3.2% | 5.4% | 12.7% | 6.9% | 4.6% | 3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Chong Kun Dang Pharmaceutical dividends
- Dividend yield
- 1.65%
- Forward dividend
- 500.00 KRW
- Payout ratio
- 17.8%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 13.8B | 1,049 | 17.8% |
| 2024 | KRW 13.3B | 1,061 | 12.2% |
| 2023 | KRW 11.6B | 912 | 5.5% |
| 2022 | KRW 11.2B | 922 | 13.9% |
| 2021 | KRW 10.8B | 915 | 25.3% |
| 2020 | KRW 9.28B | 858 | 10.1% |
| 2019 | KRW 8.84B | 817 | 16.4% |
| 2018 | KRW 8.46B | 782 | 20.0% |
| 2017 | KRW 8.46B | 740 | 15.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Dec 27, 2024.
Who owns Chong Kun Dang Pharmaceutical
- Insiders 42.10%
- Institutions 23.22%
- Public & others 34.68%
- Shares outstanding 13.2M
- Free float 7.63M
Chong Kun Dang Pharmaceutical company profile
- Company name
- Chong Kun Dang Pharmaceutical
- Ticker
- 185750.KO
- ISIN
- KR7185750007
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,170
- Fiscal year end
- December
- Address
- Chong Kun Dang Building, Seoul, South Korea
- Phone
- 82 2 2194 0300
- Website
- ckdpharm.com
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Chong Kun Dang Pharmaceutical management
4- Mr. Young-Joo KimPresident, CEO & Chairman
- GyuWoong LeeDirector & Head of Marketing
- Woo LeeDirector & HR Manager · born 1976
- Yu-kyung KwonDirector & Head of the Development Center